Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

While the makers of Ozempic have stated that its GLP-1 medication was not made to be used as a weight loss drug, nor should ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

Amylin seems to be easier on the gut than GLP-1s like Ozempic, though it may produce less weight loss. advertisement. Barron's. ... kidneys and perhaps even the brain.

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion.

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ultralong-acting challenger to candidates in development at AbbVie, Eli Lilly ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial and the potential to have longer-lasting effects than current weight loss treatments on the ...

Listening to sound doesn t just trigger brain activity it reshapes your brain s internal networks in real time. Scientists have unveiled a powerful new imaging method, FREQ-NESS, that traces how ...